Companies developing stem cell-based interventions should work with policymakers and patient advocates to address risks for current and future patients and to protect clinical research and the reputation of the field, write the authors. Read their full article in Cell & Gene Therapy Insights (free registration).
It now seems technically feasible to culture human embryos beyond the “fourteen‐day limit,” which has the potential to increase scientific understanding of human development and perhaps improve infertility treatments. Robust stakeholder engagement preceded adoption of the fourteen‐day limit and should arguably be part of efforts to reassess it, write the authors.
Kirstin R.W. Matthews, Ana S. Iltis, Daniel S. Wagner, Nuria Gallego Marquez, Jason Scott Robert, Inmaculada de Melo-Martín, Marieke Bigg, Sarah Franklin, Soren Holm, Ingrid Metzler, Matteo A. Molè, Jochen Taupitz, Giuseppe Testa, Jeremy SugarmanFebruary 26, 2021
This study leverages validated patient-reported outcomes measures to analyze the association between "financial toxicity" and quality of life and satisfaction among women undergoing ablative breast cancer surgery. Journal of the American College of Surgeons
Anaeze C. Offodile II, Christopher J. Coroneos, Yu-Li Lin, Chris Sidey-Gibbons, Malke Asaad, Brian Chin, Stefanos Boukovalas, Margaret S. Roubaud, Makesha Miggins, Donald P. BaumannDecember 21, 2020